Department of Public Health, Niigata University, Graduate School of Medical and Dental Sciences, Niigata City, Niigata Prefecture, Japan.
Pediatr Infect Dis J. 2010 Oct;29(10):898-904. doi: 10.1097/INF.0b013e3181de9d24.
Little is known about whether neuraminidase inhibitors are effective for children infected with oseltamivir-resistant influenza A(H1N1) viruses.
Children aged 15 years and younger having influenza-like illness and who visited outpatient clinics within 48 hours of fever onset were enrolled from 2006-2007 to 2008-2009 influenza seasons in Japan. Patients received oseltamivir, zanamivir, or no treatment after screening by a rapid antigen test. Nasopharyngeal swabs were collected before antiviral therapy and were used for virus isolation. Oseltamivir resistance was determined by detection of the H275Y mutation in neuraminidase, and susceptibility test using neuraminidase inhibition assay. Daily body temperature was evaluated according to drug type and susceptibility by univariate and multivariate analyses.
Of 1647 patients screened, 238 oseltamivir-resistant H1N1 cases (87 oseltamivir-treated, 64 zanamivir-treated, and 87 nontreated) and 110 oseltamivir-susceptible cases (60 oseltamivir-treated and 50 nontreated) were evaluated. In oseltamivir-resistant cases, fever on days 4 to 5 after the start of treatment was significantly higher in oseltamivir-treated and nontreated than in zanamivir-treated patients (P < 0.05). In oseltamivir-susceptible cases, fever was significantly lower in oseltamivir-treated than nontreated on days 3 to 6 (P < 0.01). Similar findings were obtained for duration of the fever and proportion of recurrent fever. Reduced effectiveness of oseltamivir was more prominent in children 0 to 6 years old than in those 7 to 15 years old. Multiple logistic regression analysis showed that lower age, nontreatment, and oseltamivir treatment of oseltamivir-resistant patients were factors associated with the duration of the longer fever.
Infection with oseltamivir-resistant viruses significantly reduced the effectiveness of oseltamivir, and this tendency was more apparent in younger children.
对于感染奥司他韦耐药型流感 A(H1N1)病毒的儿童,神经氨酸酶抑制剂是否有效尚不清楚。
2006-2007 年至 2008-2009 年流感季节,在日本,年龄在 15 岁及以下、出现流感样症状并在发热后 48 小时内就诊于门诊的患者入组。患者在进行快速抗原检测后接受奥司他韦、扎那米韦或不治疗。在开始抗病毒治疗前采集鼻咽拭子,用于病毒分离。通过神经氨酸酶抑制试验检测神经氨酸酶中的 H275Y 突变来确定奥司他韦耐药性,并进行敏感性检测。通过单变量和多变量分析,根据药物类型和敏感性评估每日体温。
在筛选的 1647 例患者中,评估了 238 例奥司他韦耐药型 H1N1 病例(87 例奥司他韦治疗、64 例扎那米韦治疗和 87 例未治疗)和 110 例奥司他韦敏感病例(60 例奥司他韦治疗和 50 例未治疗)。在奥司他韦耐药病例中,奥司他韦治疗和未治疗的患者在治疗开始后第 4-5 天的发热显著高于扎那米韦治疗的患者(P<0.05)。在奥司他韦敏感病例中,奥司他韦治疗的患者在第 3-6 天的发热显著低于未治疗的患者(P<0.01)。发热持续时间和复发性发热的比例也有类似发现。奥司他韦对 0-6 岁儿童的疗效降低比 7-15 岁儿童更为显著。多变量逻辑回归分析显示,年龄较小、未治疗和奥司他韦耐药患者的奥司他韦治疗是与发热时间延长相关的因素。
感染奥司他韦耐药型病毒显著降低了奥司他韦的疗效,而这种趋势在年龄较小的儿童中更为明显。